Daiber Andreas,Patel Sanjaykumar,Woerle Hans-Juergen,Johansen Odd-Erik,Klein Thomas,Mark Michael
申请号：
NZ71598311
公开号：
NZ715983A
申请日:
2011.11.15
申请国别(地区):
NZ
年份:
2017
代理人:
摘要：
Use of linagliptin for preparing a pharmaceutical composition for treating patients having metabolic disorders such as diabetes, who are at elevated risk of cardiovascular disorders. Where elevated cardiovascular risk is determined by one or more of the following risk factors: A) previous or existing vascular disease selected from myocardial infarction, coronary artery disease, percutaneous coronary intervention, coronary artery by-pass grafting, ischemic or hemorrhagic stroke, congestive heart failure, and peripheral occlusive arterial disease, B) vascular related end-organ damage selected from nephropathy, retinopathy, neuropathy, impaired renal function, chronic kidney disease, and micro- or macroalbuminuria, C) advanced age >/= 70 years, and D) at least two cardiovascular risk factors selected from - advanced type 2 diabetes mellitus > 10 years duration, - hypertension, - current daily cigarette smoking, - dyslipidemia, and - obesity
